About ReviR Therapeutics
ReviR Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2021 by Yang Li. RNA-based therapeutics for multiple diseases are developed using machine learning. ReviR Therapeutics has raised $50 million across 4 funding rounds from investors including XtalPi, Tiantu Investment and Lapam Capital. ReviR Therapeutics offers products and services including REVIR Platform. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
ReviR Therapeutics was established in 2021 in San Francisco, United States, within the biotechnology sector. RNA-based medicines are created for cancer, rare genetic disorders, and infectious diseases. Machine learning and advanced RNA methods are applied to support these efforts. Operations center on research and development to address unmet medical needs through targeted therapeutic approaches.
- Headquarters San Francisco, United States
- Founders Yang Li
- SectorsHealthcare
- Website revirtx.com
- Social LinkedIn
- Total Equity Funding$50M (USD)
in 4 rounds
- InvestorsXtalPi
& 9 more
Products & Services of ReviR Therapeutics
ReviR Therapeutics offers a comprehensive portfolio of products and services, including REVIR Platform.
Platform for AI-assisted RNA-based drug discovery processes.
Funding Insights of ReviR Therapeutics
ReviR Therapeutics has successfully raised a total of $50M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50M
- Total Rounds 4
- First Round $20M
(Jan 2022)
- Investors Count 10
All 4 funding rounds of ReviR Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | Series A | – | – | – | |
| Nov 2025 | $4.6M | Grant | – | State of California | – |
| Jul 2024 | $30M | Series A | – | Lapam Capital | |
| Jan 2022 | $20M | Seed | – | 5Y Capital, CDH |
10 investors in total: 10 institutional.
Investors in ReviR Therapeutics
ReviR Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include XtalPi, Tiantu Investment and Lapam Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| lapamcapital.com | ||||
Private equity and private debt firm focused on multiple sectors | cdhfund.com | Kowloon, China | ||
A venture capital firm focused on technology and innovation investments. | 5ycap.com | Shanghai, China | ||
| yaelcapital.com | ||||
Venture capital fund focused on mobile, internet, deep technology, rural internet, AI, and multiple sectors | shunwei.com | Beijing, China | ||
Tech investments are made stage-agnostically in China and the US. | sky9capital.com | Shanghai, China | ||
Private equity investments are directed toward multiple sectors. | 2002 | tiantucapital.com | Shenzhen, China | |
Research funding is provided for Charcot-Marie-Tooth disease cures. | 2018 | cmtrf.org | Atlanta, United States | |
AI-driven crystal structure prediction for pharmaceutical development is offered. | 2014 | xtalpi.com | Cambridge, United States | |
Access to government programs and development services is provided. | ca.gov |
Investor details for ReviR Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ReviR Therapeutics
10 people are tracked at ReviR Therapeutics (8 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Yang Li | Co-Founder | Leadership |
Sarah Burnett, PhD | Senior Director of Business Development | Leadership |
Peng Yue | Co-Founder, CEO | Leadership |
Sridhar Narayan | Vice President | Leadership |
Paul August | Chief Scientific Officer | Leadership |
Mary McMahon | Director, Biology | Leadership |
Jinxing Li | Associate Director | Leadership |
Jacqueline Salotti | Associate Director | Leadership |
Jeff Zhang | Senior Scientist | Team |
Kendra Lew | Senior Research Associate | Team |
Complete people profiles for ReviR Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ReviR Therapeutics
3 dated milestones of ReviR Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded ReviR Therapeutics is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series A,.
Competitors of ReviR Therapeutics
ReviR Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of ReviR Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ReviR Therapeutics
The website of ReviR Therapeutics (revirtx.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▲ 156.9% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as ReviR Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Revir Therapeutics
Complete news archive for ReviR Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReviR Therapeutics
ReviR Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
ReviR Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
ReviR Therapeutics is a funded company, having raised a total of $50M across 4 funding rounds to date. The company's 1st funding round was a Seed of $20M, raised on Jan 2022.
ReviR Therapeutics was established in 2021 in San Francisco, United States, within the biotechnology sector. RNA-based medicines are created for cancer, rare genetic disorders, and infectious diseases. Machine learning and advanced RNA methods are applied to support these efforts. Operations center on research and development to address unmet medical needs through targeted therapeutic approaches.
ReviR Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
ReviR Therapeutics offers REVIR Platform.
ReviR Therapeutics has 10 investors. Key investors include XtalPi, Tiantu Investment, Lapam Capital, CDH, and 5Y Capital.